Cutting-edge studies illuminate new frontiers in oncology. Glycan-dependent T cell recruiting (GlyTR) compounds designed at UC Irvine demonstrate pan-cancer immunotherapy efficacy by selectively targeting tumor-associated carbohydrate antigens, minimizing toxicity. UCLA researchers uncovered that IGF2BP3 protein coordinates metabolic and RNA regulation to enhance leukemia proliferation, suggesting novel therapeutic targets. Moreover, inhibitors of DDR1 amplify carbon ion therapy effectiveness in head and neck squamous cell carcinoma, indicating promising approaches for radiation sensitization.